In the last trading session, 1.46 million shares of the FibroGen Inc (NASDAQ:FGEN) were traded, and its beta was 0.83. Most recently the company’s share price was $0.38, and it changed around -$0.03 or -6.78% from the last close, which brings the market valuation of the company to $38.36M. FGEN currently trades at a discount to its 52-week high of $2.80, offering almost -636.84% off that amount. The share price’s 52-week low was $0.18, which indicates that the current value has risen by an impressive 52.63% since then.
FibroGen Inc stock received a consensus recommendation rating of Hold, based on a mean score of 2.00. If we narrow it down even further, the data shows that 0 out of 2 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 1 recommended FGEN as a Hold, whereas 0 deemed it a Buy, and 0 rated it as Underweight. FibroGen Inc is expected to report earnings per share of -0.2 for the current quarter.
FibroGen Inc (NASDAQ:FGEN) trade information
Instantly FGEN has showed a red trend with a performance of -6.78% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 0.5200 on recent trading dayincreased the stock’s daily price by 26.92%. The company’s shares are currently down -28.10% year-to-date, but still down -34.38% over the last five days. On the other hand, FibroGen Inc (NASDAQ:FGEN) is -24.25% down in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $28, which translates to bulls needing to increase their stock price by 98.64% from its current value. Analyst projections state that FGEN is forecast to be at a low of $28 and a high of $28.
FibroGen Inc (FGEN) estimates and forecasts
The year-over-year growth rate is expected to be 20.37%, up from the previous year.
Consensus estimates provided by 2 financial analysts predict the company will bring in an average of 24.91M in revenue for the current quarter. Analysts predict that the company’s current quarter sales will drop, forecast at -8.21%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -23.23%. FibroGen Inc earnings are expected to increase by 72.60% in 2025, but the outlook is positive 49.32% per year for the next five years.
FGEN Dividends
FibroGen Inc’s next quarterly earnings report is expected to be released in April.
ARMISTICE CAPITAL, LLC, with 8.9508% or 8.94 million shares worth $7.97 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Vanguard Horizon Fund-Capital Opportunity Fund and Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Dec 31, 2024 . The former held 3.5 shares worth $1.33 million, making up 3.47% of all outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held roughly 2.92 shares worth around $1.11 million, which represents about 2.89% of the total shares outstanding.
